Claims for Patent: 8,198,292

Summary for Patent: 8,198,292

Title:	Vinpocetine and eburnamonine derivatives for promoting bone growth, treating renal damage and cancer, and devices thereof
Abstract:	The present invention provides a method of promoting bone growth in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I. The compounds include the salts, hydrates and isomers thereof. The present invention also provides methods for the treatment of renal disease and cancer.
Inventor(s):	Ellies; Debra (Parkville, MO), Rosenberg; William (Overland Park, KS)
Assignee:	Osteogenex, Inc. (Kansas City, KS)
Application Number:	12/494,670
Patent Claims:	1. A method of promoting bone growth in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula I: ##STR00014## wherein each of R.sup.1, R.sup.2, R.sup.5, R.sup.7 and R.sup.8 are independently selected from the group consisting of H, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkoxy, C.sub.1-6 alkyl-hydroxy, --OR.sup.1a, --C(O)R.sup.1a, --C(O)OR.sup.1a, --C(O)NR.sup.1aR.sup.1b, --NR.sup.1aR.sup.1b, --SR.sup.1a, --N(R.sup.1a)C(O)R.sup.1b, --N(R.sup.1a)C(O)OR.sup.1b, --N(R.sup.1a)C(O)NR.sup.1aR.sup.1b, --OP(O)(OR.sup.1a).sub.2, --S(O).sub.2OR.sup.1a, --S(O).sub.2NR.sup.1aR.sup.1b, --CN, --CH.dbd.N--OH, C.sub.1-6 alkyl-OC(O)-aryl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl; alternatively, R.sup.1 is combined with R.sup.2 to form .dbd.O or .dbd.NR.sup.1a, R.sup.1 is combined with R.sup.3 to form a bond, or R.sup.1 is combined with R.sup.5 to form a cycloalkyl; each R.sup.1a and R.sup.1b is independently selected from the group consisting of H, C.sub.1-6 alkyl, C.sub.1-6 alkyl-hydroxy, C.sub.1-6 alkyl-NO.sub.2, C.sub.1-6 alkyl-cycloalkyl, heterocycloalkyl, and heteroaryl; each of R.sup.3 and R.sup.4 are independently selected from the group consisting of H, C.sub.1-6 alkyl and C.sub.1-6 haloalkyl; alternatively two R.sup.5 or R.sup.7 groups attached to the same carbon can be combined to form .dbd.O; R.sup.6 is absent or an N-oxide; and salts, hydrates and isomers thereof, thereby promoting bone growth in the subject. 2. The method of claim 1, wherein the compound has the formula: ##STR00015## 3. The method of claim 2, wherein the compound has the formula: ##STR00016## 4. The method of claim 3, wherein R.sup.1a is C.sub.1-6 alkyl; and R.sup.4 is C.sub.1-6 alkyl. 5. The method of claim 4, wherein the compound has the formula: ##STR00017## 6. The method of claim 1, wherein the compound has the formula: ##STR00018## 7. The method of claim 6, wherein the compound has the formula: ##STR00019## 8. The method of claim 1, wherein the bone growth is promoted at a site of injury or localized condition. 9. The method of claim 8, wherein the bone growth is promoted at a site selected from the group consisting of a bone fracture and weakened bone. 10. The method of claim 8, wherein the subject requires a spinal fusion, arthrodesis or an orthopedic or periodontal synthetic bone graft or implant. 11. The method of claim 8, further comprising the step of administering to the subject an osteoconductive matrix. 12. The method of claim 11, wherein the osteoconductive matrix comprises an osteoinductive agent selected from the group consisting of bone allograft, bone autograft, demineralized bone and periodontal ligament cells. 13. The method of claim 11, wherein the osteoconductive matrix comprises a calcium salt, calcium sulfate, calcium phosphate, a calcium phosphate cement, hydroxyapatite, coralline based hydroyxapatite (HA), dicalcium phosphate, tricalcium phosphate (TCP), calcium carbonate, collagen, plaster of Paris, phosphosphoryn, a borosilicate, a biocompatible ceramic, a calcium phosphate ceramic and polytetrafluoroethylene. 14. The method of claim 1, wherein the bone growth is systemic. 15. The method of claim 14, wherein the subject suffers from a low bone mass phenotype disease. 16. The method of claim 15, wherein the low bone mass phenotype disease is selected from the group consisting of osteoporosis, osteopenia, and osteoporosis-pseudoglioma syndrome (OPPG). 17. The method of claim 1, wherein the compound is administered in combination with an antiresorptive drug. 18. The method of claim 17, wherein the antiresorptive drug is selected from the group consisting of denosumab, a RankL inhibitor, a bisphosphonate, a selective estrogen receptor modulator (SERM), calcitonin, a calcitonin analog, Vitamin D and a Vitamin D analog. 19. The method of claim 17, wherein the bone growth is systemic. 20. The method of claim 17, wherein the bone growth is promoted by a local application of the compound and the antiresorptive drug. 21. A method of treating renal damage, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of Formula I: ##STR00020## wherein each of R.sup.1, R.sup.2, R.sup.5, R.sup.7 and R.sup.8 are independently selected from the group consisting of H, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkoxy, C.sub.1-6 alkyl-hydroxy, --OR.sup.1a, --C(O)R.sup.1a, --C(O)OR.sup.1a, --C(O)NR.sup.1aR.sup.1b, --NR.sup.1aR.sup.1b, --SR.sup.1a, --N(R.sup.1a)C(O)R.sup.1b, --N(R.sup.1a)C(O)OR.sup.1b, --N(R.sup.1a)C(O)NR.sup.1aR.sup.1b, --OP(O)(OR.sup.1a).sub.2, --S(O).sub.2OR.sup.1a, --S(O).sub.2NR.sup.1aR.sup.1b, --CN, --CH.dbd.N--OH, C.sub.1-6 alkyl-OC(O)-aryl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl; alternatively, R.sup.1 is combined with R.sup.2 to form .dbd.O or .dbd.NR.sup.1a, R.sup.1 is combined with R.sup.3 to form a bond, or R.sup.1 is combined with R.sup.5 to form a cycloalkyl; each R.sup.1a and R.sup.1b is independently selected from the group consisting of H, C.sub.1-6 alkyl, C.sub.1-6 alkyl-hydroxy, C.sub.1-6 alkyl-NO.sub.2, C.sub.1-6 alkyl-cycloalkyl, heterocycloalkyl, and heteroaryl; each of R.sup.3 and R.sup.4 are independently selected from the group consisting of H, C.sub.1-6 alkyl and C.sub.1-6 haloalkyl; alternatively two R.sup.5 or R.sup.7 groups attached to the same carbon can be combined to form .dbd.O; R.sup.6 is absent or an N-oxide; and salts, hydrates and isomers thereof, thereby treating renal damage in the subject. 22. An orthopedic or periodontal medical device comprising a structural support, wherein an implantable portion of the structural support is adapted to be permanently implanted within a subject, wherein the implantable portion is attached to a bone, the structural support bearing at least a partial external coating comprising a compound of Formula I: ##STR00021## wherein each of R.sup.1, R.sup.2, R.sup.5, R.sup.7 and R.sup.8 are independently selected from the group consisting of H, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkoxy, C.sub.1-6 alkyl-hydroxy, --OR.sup.1a, --C(O)R.sup.1a, --C(O)OR.sup.1a, --C(O)NR.sup.1aR.sup.1b, --NR.sup.1aR.sup.1b, --SR.sup.1a, --N(R.sup.1a)C(O)R.sup.1b, --N(R.sup.1a)C(O)OR.sup.1b, --N(R.sup.1a)C(O)NR.sup.1aR.sup.1b, --OP(O)(OR.sup.1a).sub.2, --S(O).sub.2OR.sup.1a, --S(O).sub.2NR.sup.1aR.sup.1b, --CN, --CH.dbd.N--OH, C.sub.1-6 alkyl-OC(O)-aryl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl; alternatively, R.sup.1 is combined with R.sup.2 to form .dbd.O or .dbd.NR.sup.1a, R.sup.1 is combined with R.sup.3 to form a bond, or R.sup.1 is combined with R.sup.5 to form a cycloalkyl; each R.sup.1a and R.sup.1b is independently selected from the group consisting of H, C.sub.1-6 alkyl, C.sub.1-6 alkyl-hydroxy, C.sub.1-6 alkyl-NO.sub.2, C.sub.1-6 alkyl-cycloalkyl, heterocycloalkyl, and heteroaryl; each of R.sup.3 and R.sup.4 are independently selected from the group consisting of H, C.sub.1-6 alkyl and C.sub.1-6 haloalkyl; alternatively two R.sup.5 or R.sup.7 groups attached to the same carbon can be combined to form .dbd.O; R.sup.6 is absent or an N-oxide; and salts, hydrates and isomers thereof. 23. A method of treating cancer, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of Formula I: ##STR00022## wherein each of R.sup.1, R.sup.2, R.sup.5, R.sup.7 and R.sup.8 are independently selected from the group consisting of H, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkoxy, C.sub.1-6 alkyl-hydroxy, --OR.sup.1a, --C(O)R.sup.1a, --C(O)OR.sup.1a, --C(O)NR.sup.1aR.sup.1b, --NR.sup.1aR.sup.1b, --SR.sup.1a, --N(R.sup.1a)C(O)R.sup.1b, --N(R.sup.1a)C(O)OR.sup.1b, --N(R.sup.1a)C(O)NR.sup.1aR.sup.1b, --OP(O)(OR.sup.1a).sub.2, --S(O).sub.2OR.sup.1a, --S(O).sub.2NR.sup.1aR.sup.1b, --CN, --CH.dbd.N--OH, C.sub.1-6 alkyl-OC(O)-aryl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl; alternatively, R.sup.1 is combined with R.sup.2 to form .dbd.O or .dbd.NR.sup.1a, R.sup.1 is combined with R.sup.3 to form a bond, or R.sup.1 is combined with R.sup.5 to form a cycloalkyl; each R.sup.1a and R.sup.1b is independently selected from the group consisting of H, C.sub.1-6 alkyl, C.sub.1-6 alkyl-hydroxy, C.sub.1-6 alkyl-NO.sub.2, C.sub.1-6 alkyl-cycloalkyl, heterocycloalkyl, and heteroaryl; each of R.sup.3 and R.sup.4 are independently selected from the group consisting of H, C.sub.1-6 alkyl and C.sub.1-6 haloalkyl; alternatively two R.sup.5 or R.sup.7 groups attached to the same carbon can be combined to form .dbd.O; R.sup.6 is absent or an N-oxide; and salts, hydrates and isomers thereof, wherein said cancer is amenable to the anti-cancer effect of the compound of Formula I, thereby treating cancer in the subject. 24. The method of claim 23, wherein the cancer is bone cancer, colon cancer, multiple myeloma, gastric cancer, colorectal cancer, prostate cancer, cervical cancer, lung cancer, pancreatic cancer, medulloblastoma, liver cancer, parathyroid cancer, endometrial cancer, and breast cancer.

Details for Patent 8,198,292

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	PROLIA	denosumab	Injection	125320	06/01/2010		2028-07-03
Amgen, Inc.	XGEVA	denosumab	Injection	125320	11/18/2010		2028-07-03